<DOC>
	<DOCNO>NCT00869414</DOCNO>
	<brief_summary>This research prospective , randomize , cross-over study do compare effect morning , even twice daily insulin glargine ( LantusÂ® ) hypoglycemia ( blood glucose level &lt; 70 mg/dL ) measure continuous glucose monitoring ( CGM ) patient type 1 diabetes .</brief_summary>
	<brief_title>Glycemic Effects Morning Only , Evening Only Twice Daily Insulin Glargine Patients With Type 1 Diabetes</brief_title>
	<detailed_description>Over course 6 week study , patient take insulin glargine 3 different time : morning , night , half morning , half night . After 2 week take insulin one regimen , patient switch another regimen . Through whole study , patient inject twice daily , neither patient treat doctor know vial contain insulin saline ( placebo ) . The vial label MORNING EVENING . Patients continue take mealtime , short act insulin dos . Additionally , patient wear continuous glucose monitor ( CGM ) mask . Before study , patient teach use CGM , keep taped abdomen . The site CGM insert abdomen need change every 5 day . We know patient ' blood sugar go low even patient feel low . Patients still self-monitor blood sugar level at-least four time five day , calibrate CGM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Adult men woman age 18 diagnosis type 1 diabetes mellitus On multiple insulin injection , include long acting intermediate act insulin preparation mealtime short act insulin preparation . Clinical history consistent hypoglycemia Hba1c &lt; 9.0 % Patients type 2 diabetes mellitus Patients insulin pump Poor control diabetes ( HbA1c &gt; 9.0 % ) Pregnancy ( woman childbearing age undergo pregnancy test start study advise use birth control method study ) . Insulin glargine report teratogenic effect animal model , therefore used pregnancy clearly need . Serious comorbidities , clinical opinion investigator , could affect pharmacokinetics glargine ( e.g. , CRF ) safety ( e.g. , recent CAD )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>hypoglycemia</keyword>
	<keyword>type 1 diabetes</keyword>
	<keyword>split dose insulin glargine</keyword>
	<keyword>continuous glucose monitoring</keyword>
</DOC>